Search

Your search keyword '"Gulminetti, R."' showing total 220 results

Search Constraints

Start Over You searched for: Author "Gulminetti, R." Remove constraint Author: "Gulminetti, R."
220 results on '"Gulminetti, R."'

Search Results

102. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

103. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

104. Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir

105. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

106. Incident diabetes in course of antiretroviral therapy

107. Trajectories of CD4+/CD8+ T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study

108. Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti?

109. Plasma Levels of Bacterial DNA in HIV Infection: The Limits of Quantitative Polymerase Chain Reaction

110. Fattori associati con il ricovero ospedaliero per COVID-19 in 80 pazienti HIV-positivi italiani. Factors associated with hospital admission for COVID-19 in 80 Italian HIV patients

111. Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project

112. Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy

113. Dolutegravir safety in a real-life setting: results Title from the SCOLTA cohort

114. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

115. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

116. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

117. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

118. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

119. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

120. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study

121. Performance of genotypic tropism testing on proviral DNA in clinical practice: Results from the DIVA study group

122. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience

124. Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study.

125. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study.

127. Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.

128. Pillars of long-term antiretroviral therapy success.

129. Incident diabetes in course of antiretroviral therapy.

130. Trajectories of CD4 + /CD8 + T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study.

131. Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.

132. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

133. Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies.

134. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study.

135. A challenging case of SARS-CoV-2- AIDS and Nocardiosis coinfection from the SMatteo COvid19 REgistry (SMACORE).

136. Patients with chronic hepatitis C receiving treatment with direct acting antivirals: How is this population changing?

137. Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients.

138. Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort.

139. Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs.

140. Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study.

141. Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.

142. Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.

143. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.

144. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.

145. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.

147. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.

148. Development and persistence of DAA resistance associated mutations in patients failing HCV treatment.

149. Phylogenetic analysis of HIV type 1 CRF02_AG in multiple genes in Italian and African patients living in Italy.

150. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma.

Catalog

Books, media, physical & digital resources